Renovaro Biosciences Denmark ApS: Financial statements 2013
CVR: 26027322
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
Renovaro Biosciences Denmark ApS (CVR 26027322) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -5,558,844 and a net result of DKK -10,561,248. Equity in the 2013 report amounted to DKK -9,478,553.
- Gross Profit
- DKK -5,558,844
- Profit/Loss
- DKK -10,561,248
- Equity
- DKK -9,478,553
- Total Assets
- DKK 2,075,596
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of September 6, 2013, CROWE STATSAUTORISERET REVISIONSINTERESSENTSKAB has been appointed auditor of Renovaro Biosciences Denmark ApS.
As of September 6, 2013, Beierholm Godkendt Revisionspartnerselskab has stepped down as auditor of Renovaro Biosciences Denmark ApS.
Renovaro Biosciences Denmark ApS has published its annual report for 2012.
As of June 19, 2013, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Renovaro Biosciences Denmark ApS.
As of June 19, 2013, BAAGØE SCHOU STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of Renovaro Biosciences Denmark ApS.
As of June 19, 2013, Niels Erik Nielsen has joined the board of directors of Renovaro Biosciences Denmark ApS.
As of June 19, 2013, Jacob Rosenberg has joined the board of directors of Renovaro Biosciences Denmark ApS.
As of June 19, 2013, Aldo Michael Noes Petersen has joined the board of directors of Renovaro Biosciences Denmark ApS.
As of June 19, 2013, Knud Carsten Bernhard Lønfeldt has left the board of directors of Renovaro Biosciences Denmark ApS.
As of June 19, 2013, Peter Buhl has left the board of directors of Renovaro Biosciences Denmark ApS.
About Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Enochian BioSciences Denmark ApS and DanDrit Biotech ApS. The management consists of David Hershel Weinstein. The company is owned by Lunai Bioworks Inc.. The company has 1 employee (2017). In 2026, the company reported a gross profit of DKK -4,478 and a net result of DKK -1,178,038 compared with DKK -4,629,959 the year before. Equity in the 2026 report amounted to DKK -91,933,986.
